The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Tech in AsiaAsia

Who’s investing in India’s biotech startups?

September 28

We've compiled a list of investors pouring money into India’s biotech startups.

Read at Tech in Asia ↗

One letter a week, in your inbox.

Latest

Who’s investing in India’s biotech startups?

More from Tech in Asia on Accept All

AsiaWhy this founder killed his AI startup despite early success Tech in Asia

AsiaChina weighs Nvidia chip purchases by ByteDance, Alibaba Tech in Asia

AsiaThese are the most active investors in Hong Kong’s startups Tech in Asia

AsiaThe 50 top-funded AI startups in Asia Tech in Asia

AsiaSingapore proposes UN framework for AI safety rules Tech in Asia

AsiaApple ordered to pay $5.7b over haptic technology patents Tech in Asia